OPTIMIZING CHEMICAL STRUCTURE OF ANTIPNEUMOCYSTIS AGENTS

Information

  • Research Project
  • 2794690
  • ApplicationId
    2794690
  • Core Project Number
    R15AI044602
  • Full Project Number
    1R15AI044602-01
  • Serial Number
    44602
  • FOA Number
    PA-97-52
  • Sub Project Id
  • Project Start Date
    3/15/1999 - 25 years ago
  • Project End Date
    3/14/2002 - 22 years ago
  • Program Officer Name
    LAUGHON, BARBARA E.
  • Budget Start Date
    3/15/1999 - 25 years ago
  • Budget End Date
    3/14/2002 - 22 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/18/1999 - 25 years ago

OPTIMIZING CHEMICAL STRUCTURE OF ANTIPNEUMOCYSTIS AGENTS

DESCRIPTION (Adapted from Applicant's Abstract): Pneumocystis carinii is a microorganism that causes pneumonia in immunocompromised patients. The principal goal of this project is the improvement of both prophylaxis and treatment of P. carinii pneumonia through the development of a drug with high ratio of efficacy to toxicity.The specific aims of this proposal are: (1) to select a set of active, moderately active, and inactive compounds; (2) to generate a preliminary hypothesis to explain activity in terms of chemical structure; (3) to evaluate the hypothesis against other compounds of various activities; (4) to search databases for compounds that fit the hypothesis; (5) to test in vitro the compounds that best fit the hypothesis for activity against P. carinii; and (6) to test in vivo the compounds that show the greatest activity in vitro. Beginning with observed activity values, computer-based methods for elucidating quantitative structure-activity relationships (QSAR) will be used to identify chemical functions (e.g., hydrogen bond donor, hydrophobic group, positive ionizable group), with coordinates in 3-dimensional space, that likely account for anti- Pneumocystis activity. To complete these structural hypotheses, computational molecular modeling will be used to identify substructures (e.g., alkyl, amino, halo) that further effect activity. Compounds that meet the structural criteria for activity will be tested in vitro. The most active compounds will then be tested in vivo under an existing arrangement with National Institutes of Health.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R15
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG5
  • Study Section Name
  • Organization Name
    ROSE-HULMAN INSTITUTE OF TECHNOLOGY
  • Organization Department
    ENGINEERING (ALL TYPES)
  • Organization DUNS
    052008414
  • Organization City
    TERRE HAUTE
  • Organization State
    IN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    478033999
  • Organization District
    UNITED STATES